Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 4
1965 8
1966 27
1967 28
1968 34
1969 21
1970 19
1971 27
1972 32
1973 25
1974 23
1975 20
1976 22
1977 21
1978 25
1979 15
1980 19
1981 14
1982 8
1983 18
1984 13
1985 19
1986 16
1987 17
1988 13
1989 26
1990 13
1991 14
1992 22
1993 19
1994 30
1995 21
1996 43
1997 42
1998 36
1999 53
2000 53
2001 47
2002 47
2003 52
2004 45
2005 74
2006 67
2007 60
2008 88
2009 74
2010 86
2011 95
2012 105
2013 107
2014 88
2015 64
2016 61
2017 62
2018 67
2019 50
2020 47
2021 48
2022 51
2023 48
2024 53
2025 61
2026 35

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,256 results

Results by year

Filters applied: . Clear all
Page 1
Modafinil Versus Amphetamine-Dextroamphetamine For Idiopathic Hypersomnia and Narcolepsy Type 2: A Randomized, Blinded, Non-inferiority Trial.
Trotti LM, Blake T, Hoque R, Rye DB, Sharma S, Bliwise DL. Trotti LM, et al. CNS Drugs. 2024 Nov;38(11):909-920. doi: 10.1007/s40263-024-01122-y. Epub 2024 Sep 21. CNS Drugs. 2024. PMID: 39306601 Free PMC article. Clinical Trial.
METHODS: Forty-four adults were randomized to modafinil or amphetamine-dextroamphetamine, individually titrated to a maximum of modafinil 200 mg twice daily or amphetamine-dextroamphetamine 20 mg twice daily, for 12 weeks. ...RESULTS: Epworth improved …
METHODS: Forty-four adults were randomized to modafinil or amphetamine-dextroamphetamine, individually titrated to a maximum o …
Amphetamine abuse.
Ellinwood EH, Cohen S. Ellinwood EH, et al. Science. 1971 Jan 29;171(3969):420-1. doi: 10.1126/science.171.3969.420. Science. 1971. PMID: 4923360 Clinical Trial. No abstract available.
The effects of caffeine and d-amphetamine on spatial span task in healthy participants.
Kassim FM, Lim JHM, Slawik SV, Gaus K, Peters B, Lee JWY, Hepple EK, Rodger J, Albrecht MA, Martin-Iverson MT. Kassim FM, et al. PLoS One. 2023 Jul 13;18(7):e0287538. doi: 10.1371/journal.pone.0287538. eCollection 2023. PLoS One. 2023. PMID: 37440493 Free PMC article. Clinical Trial.
RESULTS: We failed to find an effect of d-amphetamine or caffeine on SWM or VWM, relative to placebo. However, d-amphetamine increased a composite score of psychosis-like experiences (p = 0.0005), specifically: Scores on Brief Psychiatric Rating Scale, Perceptual Ab …
RESULTS: We failed to find an effect of d-amphetamine or caffeine on SWM or VWM, relative to placebo. However, d-amphetamine i …
Biological and behavioral responses to D-amphetamine, alone and in combination with the serotonin3 receptor antagonist ondansetron, in healthy volunteers.
Grady TA, Broocks A, Canter SK, Pigott TA, Dubbert B, Hill JL, Murphy DL. Grady TA, et al. Psychiatry Res. 1996 Aug 30;64(1):1-10. doi: 10.1016/0165-1781(96)02884-3. Psychiatry Res. 1996. PMID: 8888359 Free article. Clinical Trial.
This study examined the potential interactions of the 5-HT3 antagonist ondansetron and D-amphetamine in 10 healthy human volunteers. After the subjects were pretreated with placebo or ondansetron (0.15 mg/kg, i.v.), 5-h challenge tests with oral D-amphetamine (0.5 m …
This study examined the potential interactions of the 5-HT3 antagonist ondansetron and D-amphetamine in 10 healthy human volunteers. …
Amphetamine-induced dopamine release and impulsivity in Parkinson's disease.
Song AK, Hay KR, Trujillo P, Aumann M, Stark AJ, Yan Y, Kang H, Donahue MJ, Zald DH, Claassen DO. Song AK, et al. Brain. 2022 Oct 21;145(10):3488-3499. doi: 10.1093/brain/awab487. Brain. 2022. PMID: 34951464 Free PMC article. Clinical Trial.
Twenty patients with Parkinson's disease (mean age = 64.1 5.8 years) both with (n = 10) and without (n = 10) impulsive-compulsive behaviours, participated in a single-blind dextroamphetamine challenge (oral; 0.43 mg/kg) in an OFF dopamine state. All completed PET imaging …
Twenty patients with Parkinson's disease (mean age = 64.1 5.8 years) both with (n = 10) and without (n = 10) impulsive-compulsive behaviou …
Urinary phenethylamine response to d-amphetamine in 12 boys with attention deficit disorder.
Zametkin AJ, Brown GL, Karoum F, Rapoport JL, Langer DH, Chuang LW, Wyatt RJ. Zametkin AJ, et al. Am J Psychiatry. 1984 Sep;141(9):1055-8. doi: 10.1176/ajp.141.9.1055. Am J Psychiatry. 1984. PMID: 6380319 Clinical Trial.
Urinary phenethylamine (PEA), an endogenous amine similar to amphetamine in both molecular structure and pharmacological properties, was studied in 12 boys with attention deficit disorder with hyperactivity. d-Amphetamine and placebo were given for 14 days each in a …
Urinary phenethylamine (PEA), an endogenous amine similar to amphetamine in both molecular structure and pharmacological properties, …
D-amphetamine in obsessive-compulsive disorder.
Insel TR, Hamilton JA, Guttmacher LB, Murphy DL. Insel TR, et al. Psychopharmacology (Berl). 1983;80(3):231-5. doi: 10.1007/BF00436159. Psychopharmacology (Berl). 1983. PMID: 6412267 Clinical Trial.
In a double-blind crossover study, single doses of d-amphetamine and placebo were administered to 12 patients with severe chronic obsessive-compulsive disorder (OCD). ...Changes were also significant for self-rated measures of activation and altered reality. The behavior r …
In a double-blind crossover study, single doses of d-amphetamine and placebo were administered to 12 patients with severe chronic obs …
Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine.
Avram M, Fortea L, Wollner L, Coenen R, Korda A, Rogg H, Holze F, Vizeli P, Ley L, Radua J, Müller F, Liechti ME, Borgwardt S. Avram M, et al. Mol Psychiatry. 2025 Apr;30(4):1297-1307. doi: 10.1038/s41380-024-02734-y. Epub 2024 Sep 11. Mol Psychiatry. 2025. PMID: 39261671 Free PMC article. Clinical Trial.
While LSD uniquely reduced integrity in the default-mode network (DMN), the amphetamines, in contrast to our expectations, reduced integrity in more networks than LSD. However, LSD exhibited more pronounced segregation effects, characterized solely by decreases, in contras …
While LSD uniquely reduced integrity in the default-mode network (DMN), the amphetamines, in contrast to our expectations, reduced in …
d-Amphetamine Transdermal System in Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Secondary Endpoint Results and Post Hoc Effect Size Analyses from a Pivotal Trial.
Cutler AJ, Suzuki K, Starling B, Balakrishnan K, Komaroff M, Meeves S, Castelli M, Childress A. Cutler AJ, et al. J Child Adolesc Psychopharmacol. 2023 Jun;33(5):176-182. doi: 10.1089/cap.2023.0005. J Child Adolesc Psychopharmacol. 2023. PMID: 37339441 Free PMC article. Clinical Trial.
Objectives: Amphetamines are a preferred treatment for attention-deficit/hyperactivity disorder (ADHD), with the dextroamphetamine transdermal system (d-ATS) providing an alternative to oral formulations. ...
Objectives: Amphetamines are a preferred treatment for attention-deficit/hyperactivity disorder (ADHD), with the dextroamphetamine …
Effective Connectivity of Thalamocortical Interactions Following d-Amphetamine, LSD, and MDMA Administration.
Avram M, Müller F, Preller KH, Razi A, Rogg H, Korda A, Holze F, Vizeli P, Ley L, Liechti ME, Borgwardt S. Avram M, et al. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 May;9(5):522-532. doi: 10.1016/j.bpsc.2023.07.010. Epub 2023 Jul 31. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024. PMID: 37532129 Free article. Clinical Trial.
METHODS: We used a double-blind, placebo-controlled, crossover design and administered lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), and d-amphetamine in 25 healthy participants. By using spectral dynamic causal modeling, we mapped substance-i …
METHODS: We used a double-blind, placebo-controlled, crossover design and administered lysergic acid diethylamide (LSD), 3,4-methylenedioxym …
2,256 results